# Human Rating Form — GDgpt Clinical Utility Evaluation

> **Instructions**: Rate each question on D1-D5 (1=Poor, 3=Adequate, 5=Excellent).
> Fill in the table below. Use same rubric as the LLM judge.
> Return this file after completion.

## Rubric Summary
- **D1 Factual Accuracy**: Are gene/pathway/drug claims correct?
- **D2 Completeness**: Are key evidence items covered?
- **D3 Traceability**: Are claims attributed to specific sources/edges?
- **D4 Clinical Safety**: Does it acknowledge uncertainty vs. fabricate?
- **D5 Coherence**: Is it logically structured and readable?

---
## Question 1: `ind_dc_894be162ddbb`
**Q**: What genes and pathways are associated with hereditary breast ovarian cancer syndrome? What are the key mechanisms?

### System A (GDgpt)
```
Hereditary breast ovarian cancer syndrome is ASSOCIATED_WITH mutations in pivotal genes such as **TP53**, **PIK3CA**, **KRAS**, **HRAS**, and **SRC**, which are CONFIRMED_BY the knowledge graph to dysregulate key signaling pathways. These include the **PI3K/AKT signaling** and **RAF/MAP kinase cascade**, which are INVOLVED_IN promoting tumor proliferation, survival, and genomic instability. Additionally, immune-related pathways such as **Interleukin-4 and Interleukin-13 signaling** (ASSOCIATED_WITH genes **NOS2, ALOX5, PTGS2, HMOX1, MAOA**) and **Neutrophil degranulation** (ASSOCIATED_WITH genes **APRT, ALOX5, MME, GSTP1, HPSE**) may modulate the tumor microenvironment, potentially influencing disease progression. Confidence in this conclusion is HIGH due to robust KG evidence linking gene
```

### System B (GPT-4o)
```
Hereditary Breast Ovarian Cancer (HBOC) syndrome is primarily associated with pathogenic variants in the **BRCA1** and **BRCA2** genes, which are tumor suppressor genes critical for DNA damage repair. Mutations in these genes disrupt the homologous recombination (HR) repair pathway, leading to genomic instability and increased cancer risk. Other genes involved in HBOC syndrome include **PALB2**, **RAD51C**, **RAD51D**, and **BRIP1**, which also play roles in DNA repair.

### Key Pathways and Mechanisms:
1. **Homologous Recombination DNA Repair Deficiency (HRD):**
   - BRCA1 and BRCA2 are essential for error-free repair of double-strand DNA breaks via homologous recombination.
   - Loss-of-function mutations in these genes lead to HRD, forcing cells to rely on error-prone repair pathways, s
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 2: `ind_dc_22d4a0eb6658`
**Q**: What genes and pathways are associated with hereditary breast carcinoma? What are the key mechanisms?

### System A (GDgpt)
```
Hereditary breast carcinoma is ASSOCIATED_WITH mutations in both oncogenes (e.g., KRAS, HRAS, PIK3CA, SRC) and tumor suppressor genes (e.g., TP53, BRCA1), which collectively dysregulate critical cellular pathways per the knowledge graph. KRAS and HRAS mutations are INVOLVED_IN the activation of proliferative signaling pathways such as the RAF/MAP kinase cascade, while PIK3CA mutations drive the PIP3 activates AKT signaling pathway, promoting tumor growth and survival. TP53 is ASSOCIATED_WITH apoptosis-related pathways, including Activation of NOXA and PUMA and their translocation to mitochondria, while BRCA1 is INVOLVED_IN DNA repair pathways such as the Defective DNA double strand break response and the G2/M DNA damage checkpoint. Additionally, estrogen receptor genes like ESR1 and downst
```

### System B (GPT-4o)
```
Hereditary breast carcinoma is primarily associated with germline mutations in genes involved in DNA damage repair and cell cycle regulation. The following genes and pathways are most commonly implicated:

### **Key Genes:**
1. **BRCA1 and BRCA2:** 
   - These are tumor suppressor genes crucial for homologous recombination (HR)-mediated DNA repair.
   - Mutations lead to defective DNA repair, genomic instability, and increased risk of breast and ovarian cancers.
   
2. **TP53:**
   - Encodes the p53 protein, a key regulator of cell cycle arrest, apoptosis, and DNA repair.
   - Germline mutations cause Li-Fraumeni syndrome, significantly increasing breast cancer risk.

3. **PTEN:**
   - Mutations are associated with Cowden syndrome, a condition characterized by a high risk of breast cancer 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 3: `ind_dc_87845f398756`
**Q**: What genes and pathways are associated with breast neoplasm? What are the key mechanisms?

### System A (GDgpt)
```
** The knowledge graph confirms that **KRAS**, **HRAS**, **PIK3CA**, **SRC**, **TP53**, **POLR2F**, **HSP90AA1**, and **EP300** are **ASSOCIATED_WITH** **breast neoplasm**. Key oncogenes such as **KRAS**, **HRAS**, and **PIK3CA** are **INVOLVED_IN** critical pathways like the **RAF/MAP kinase cascade** and **PI3K/AKT signaling pathways** (e.g., **Activated NTRK2 signals through PI3K** and **CD28-dependent PI3K/Akt signaling**), promoting cancer cell survival and proliferation. The tumor suppressor **TP53** is **INVOLVED_IN** apoptosis-regulating pathways, such as **Activation of NOXA and translocation to mitochondria**, and its mutation may disrupt tumor suppression. Hormone receptor-positive breast cancer is influenced by **ESR1**, **BCL2**, and **CCND1**, which are **INVOLVED_IN** the **
```

### System B (GPT-4o)
```
Breast neoplasms are associated with several key genes and pathways that drive tumorigenesis, progression, and therapeutic resistance. Below is a concise outline of the most relevant genes, pathways, and mechanisms:

### **Genes Frequently Associated with Breast Neoplasm:**
1. **Tumor Suppressor Genes:**
   - **TP53**: Regulates cell cycle arrest, apoptosis, and DNA repair. Mutations are common in triple-negative breast cancer (TNBC).
   - **BRCA1/BRCA2**: Critical for homologous recombination (HR) DNA repair. Germline mutations increase the risk for hereditary breast and ovarian cancer syndromes.
   - **PTEN**: Regulates PI3K/AKT signaling and cell survival. Loss of PTEN is associated with aggressive phenotypes.

2. **Oncogenes:**
   - **PIK3CA**: Activates the PI3K/AKT/mTOR pathway, prom
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 4: `ind_dc_2000b5e3f24d`
**Q**: What genes and pathways are associated with squamous cell carcinoma of the corpus uteri? What are the key mechanisms?

### System A (GDgpt)
```
Squamous cell carcinoma of the corpus uteri is ASSOCIATED_WITH oncogenic mutations in **KRAS**, **HRAS**, and **PIK3CA**, which lead to the activation of proliferative and survival pathways such as the **RAF/MAP kinase cascade** (KRAS–INTERACTS_WITH–RAF/MAP kinase cascade) and **PIP3 activates AKT signaling** (PIK3CA–INTERACTS_WITH–PIP3 activates AKT signaling) per the knowledge graph. Loss of the tumor suppressor **TP53** (TP53–ASSOCIATED_WITH–squamous cell carcinoma of the corpus uteri) impairs apoptosis and genomic stability, as evidenced by its interaction with apoptosis-related pathways like **Activation of NOXA and translocation to mitochondria** (TP53–INTERACTS_WITH–Activation of NOXA and translocation to mitochondria). Immune modulation and inflammation are implicated through **Int
```

### System B (GPT-4o)
```
Squamous cell carcinoma of the corpus uteri is a rare subtype of endometrial cancer, and its molecular characterization is not as well-defined as other histologic types, such as endometrioid or serous endometrial carcinomas. However, based on existing knowledge, the following genes and pathways have been implicated:

### Key Genes:
1. **TP53**: Mutations in TP53 are commonly associated with aggressive features and poor prognosis in endometrial carcinomas, including rare squamous cell variants.
2. **PIK3CA** and **PTEN**: Alterations in the PI3K/AKT/mTOR signaling pathway are frequently seen in endometrial cancers, including squamous and mixed histologies.
3. **KRAS**: Mutations in KRAS may contribute to tumorigenesis in certain variants of endometrial cancers.
4. **CDKN2A (p16)**: Loss of 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 5: `ind_dc_efd557a940d1`
**Q**: What genes and pathways are associated with undifferentiated carcinoma of the corpus uteri? What are the key mechanisms?

### System A (GDgpt)
```
Undifferentiated carcinoma of the corpus uteri is strongly associated with dysregulation of oncogenic and tumor-suppressive pathways, as confirmed by the knowledge graph. Genes such as **KRAS**, **HRAS**, and **SRC** are ASSOCIATED_WITH the disease and INVOLVED_IN the **RAF/MAP kinase cascade**, which drives cell proliferation and survival. Drugs targeting this pathway, such as **MEK inhibitors** (e.g., trametinib), may be explored. Similarly, **PIK3CA** and **AKT1** are ASSOCIATED_WITH the disease and INVOLVED_IN the **PIP3 activates AKT signaling** pathway, which promotes tumor progression; potential therapies include **PI3K inhibitors** (e.g., alpelisib) and **AKT inhibitors** (e.g., ipatasertib). Hormonal dysregulation is implicated via **ESR1** and **BCL2**, which are ASSOCIATED_WITH 
```

### System B (GPT-4o)
```
Undifferentiated carcinoma of the corpus uteri is a rare and aggressive subtype of endometrial cancer characterized by high-grade histology and loss of differentiation. Its molecular mechanisms are not fully understood, but studies have identified several key genes and pathways associated with its pathogenesis:

### **Key Genes:**
1. **SWI/SNF Complex Genes**:
   - **SMARCA4**: Loss-of-function mutations in SMARCA4 (BRG1) are implicated in undifferentiated carcinoma, leading to defects in chromatin remodeling.
   - **ARID1A**: Mutations in ARID1A, another component of the SWI/SNF chromatin remodeling complex, are frequently seen in aggressive endometrial carcinomas.

2. **TP53**:
   - Mutations in TP53 are common in undifferentiated and high-grade endometrial carcinomas, leading to loss of
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 6: `ind_dc_182a1e726ac1`
**Q**: What genes and pathways are associated with schizophrenia? What are the key mechanisms?

### System A (GDgpt)
```
Schizophrenia is ASSOCIATED_WITH a network of genes, including **GRB2**, **PIK3CA**, **MAPK1**, **MAPK3**, **AKT1**, **FGF2**, and **H2AX**, which are INVOLVED_IN critical pathways per the knowledge graph. These pathways include the **RAF/MAP kinase cascade** (INVOLVED_IN neuronal signaling and plasticity via genes such as **MAPK1** and **MAPK3**), **PI3K/AKT signaling** (INVOLVED_IN cell survival and synaptic plasticity via genes such as **AKT1**, which interacts with pathways like **AKT phosphorylates targets in the cytosol**, **AKT phosphorylates targets in the nucleus**, and **AKT-mediated inactivation of FOXO1A**), immune-inflammatory pathways such as **Interleukin-4 and Interleukin-13 signaling** and **Neutrophil degranulation** (INVOLVED_IN neuroinflammation via genes such as **PTGS
```

### System B (GPT-4o)
```
Schizophrenia is a complex neuropsychiatric disorder with both genetic and environmental contributors. While no single gene is solely responsible, several genes and pathways have been implicated in its pathogenesis. Below is a concise summary of key genes, pathways, and mechanisms:

### Key Genes:
1. **COMT (Catechol-O-Methyltransferase):** Involved in dopamine metabolism; polymorphisms (e.g., Val158Met) may affect dopamine signaling in the prefrontal cortex.
2. **DISC1 (Disrupted in Schizophrenia 1):** Plays a role in neuronal development, synaptic signaling, and brain connectivity.
3. **NRG1 (Neuregulin 1):** Involved in synaptic plasticity and myelination.
4. **DRD2 (Dopamine D2 Receptor):** A key target of antipsychotic medications; altered dopamine receptor signaling is central to sch
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 7: `ind_dc_9c33ed784d74`
**Q**: What genes and pathways are associated with colorectal cancer? What are the key mechanisms?

### System A (GDgpt)
```
Colorectal cancer is driven by mutations in key oncogenes such as **KRAS**, **PIK3CA**, and **NRAS**, as well as tumor suppressor genes like **TP53** and **EP300**, which are ASSOCIATED_WITH colorectal cancer per the knowledge graph. These mutations activate critical oncogenic pathways, including the **RAS/MAPK** and **PI3K/AKT/mTOR** pathways, promoting uncontrolled cell proliferation and survival (e.g., KRAS and NRAS are ASSOCIATED_WITH colorectal cancer and INTERACT_WITH Activated NTRK2/3 pathways). Loss of function in **TP53** disrupts tumor suppression, cell cycle regulation, and apoptosis, contributing to genetic instability and cancer progression (TP53 is ASSOCIATED_WITH colorectal cancer). Inflammation and immune dysregulation, mediated by pathways such as **Neutrophil degranulatio
```

### System B (GPT-4o)
```
Colorectal cancer (CRC) is associated with a complex interplay of genetic alterations and dysregulated signaling pathways. Key genes and pathways involved include:

### 1. **APC/β-Catenin (Wnt Signaling Pathway):**
   - **Genes:** APC (tumor suppressor), CTNNB1 (encodes β-catenin).
   - **Mechanism:** Loss-of-function mutations in APC lead to aberrant activation of Wnt signaling, allowing β-catenin to accumulate and translocate to the nucleus, where it drives transcription of oncogenic target genes like MYC and CCND1.

### 2. **TP53 (Tumor Suppressor Pathway):**
   - **Gene:** TP53.
   - **Mechanism:** Mutations in TP53 disrupt cell cycle arrest, apoptosis, and DNA repair, promoting genomic instability and tumor progression.

### 3. **KRAS/NRAS and MAPK Pathway:**
   - **Genes:** KRAS, NRA
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 8: `ind_dc_6847df815fd5`
**Q**: What genes and pathways are associated with familial prostate carcinoma? What are the key mechanisms?

### System A (GDgpt)
```
Familial prostate carcinoma is ASSOCIATED_WITH dysregulated oncogenic pathways, tumor suppressor mechanisms, immune dysregulation, and potentially DNA repair processes. Specifically, the genes **KRAS**, **HRAS**, **PIK3R1**, **PIK3CA**, **AKT1**, and **EGFR** are ASSOCIATED_WITH the **PI3K/AKT signaling pathway**, including sub-pathways such as **PI5P, PP2A and IER3 regulate PI3K/AKT signaling** and **PIP3 activates AKT signaling**, which promote cell survival, proliferation, and metabolism. Additionally, **KRAS**, **HRAS**, **MAPK3**, and **PIK3R1** are ASSOCIATED_WITH the **RAF/MAP kinase cascade**, which drives cell growth and differentiation. The tumor suppressor gene **TP53** is ASSOCIATED_WITH familial prostate carcinoma, and its loss or mutation can lead to genomic instability and t
```

### System B (GPT-4o)
```
Familial prostate carcinoma is associated with several genes and pathways that influence hereditary predisposition and tumorigenesis. Key genes and mechanisms include:

### **Genes and Pathways**
1. **DNA Damage Repair Pathways**
   - **BRCA1/BRCA2**: Mutations in these genes, primarily known for their role in breast and ovarian cancers, are also implicated in prostate cancer, especially aggressive forms. They impair homologous recombination repair of DNA damage, leading to genomic instability.
   - **ATM**: A gene involved in DNA damage response. Loss-of-function mutations in ATM can lead to defective repair mechanisms and increased cancer risk.
   - **CHEK2**: Encodes a checkpoint kinase involved in DNA repair. Mutations in CHEK2 are linked to familial prostate cancer due to impaired cel
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 9: `ind_dc_d746db37c9cf`
**Q**: What genes and pathways are associated with prostate cancer? What are the key mechanisms?

### System A (GDgpt)
```
Prostate cancer is mechanistically driven by dysregulation of oncogenes such as **KRAS**, **HRAS**, **PIK3CA**, **PIK3R1**, **EGFR**, and **AKT1**, as well as the tumor suppressor **TP53**, which are ASSOCIATED_WITH prostate cancer per the knowledge graph. These genes regulate critical pathways, including the **PI3K/AKT signaling** pathway (INVOLVED_IN by **PIK3R1**, **PIK3CA**, **AKT1**, and **EGFR**) and the **RAF/MAPK kinase cascade** pathway (INVOLVED_IN by **KRAS**, **HRAS**, **EGFR**, and **MAPK3**), both of which promote tumor proliferation, survival, and resistance to apoptosis. Immune modulation pathways, such as **Interleukin-4 and Interleukin-13 signaling** (INVOLVED_IN by **ALOX5**, **MMP9**, and **VEGFA**) and **Neutrophil degranulation** (INVOLVED_IN by **ALOX5**, **GSTP1**, 
```

### System B (GPT-4o)
```
Prostate cancer is associated with several genes and pathways that are implicated in tumor initiation, progression, and resistance to therapy. Below is a concise summary:

### Key Genes Associated with Prostate Cancer:
1. **Androgen Receptor (AR)**: Central to prostate cancer. AR signaling drives tumor growth in androgen-sensitive disease and remains active in castration-resistant prostate cancer (CRPC).
2. **PTEN**: Loss of this tumor suppressor gene leads to activation of the PI3K/AKT/mTOR pathway, promoting cell survival and proliferation.
3. **TP53**: Mutations in this tumor suppressor gene are associated with aggressive prostate cancer phenotypes and resistance to treatment.
4. **RB1**: Alterations in RB1 are linked to progression to CRPC and neuroendocrine prostate cancer.
5. **BRCA1
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 10: `ind_dc_3bb0a1cdbe69`
**Q**: What genes and pathways are associated with hepatocellular carcinoma? What are the key mechanisms?

### System A (GDgpt)
```
Hepatocellular carcinoma (HCC) is ASSOCIATED_WITH key oncogenes and tumor suppressor genes, including KRAS, HRAS, PIK3CA, EGFR, TP53, PSMA4, FGF4, and RAC1, as confirmed by the knowledge graph. These genes are INVOLVED_IN critical pathways that drive HCC pathogenesis. KRAS and HRAS are linked to the RAS/RAF/MEK/ERK pathway, promoting proliferative signaling, while PIK3CA and EGFR regulate the PI3K/AKT/mTOR pathway, which is crucial for cell survival and growth. TP53, a tumor suppressor, INTERACTS_WITH mitochondrial apoptotic pathways such as Activation of NOXA and PUMA, playing a pivotal role in apoptosis regulation. RAC1 is INVOLVED_IN the RHO GTPases Activate Formins pathway, contributing to cytoskeletal remodeling and tumor metastasis. PSMA4 is linked to chromatid separation pathways, s
```

### System B (GPT-4o)
```
Hepatocellular carcinoma (HCC) is associated with several genetic alterations and pathways that drive tumor development and progression. Below is a summary of key genes, pathways, and mechanisms involved:

### 1. **Key Genes Associated with HCC**
   - **TP53**: Frequently inactivated in HCC, leading to loss of cell cycle regulation and genomic instability.
   - **CTNNB1 (β-catenin)**: Activating mutations result in constitutive activation of the Wnt/β-catenin signaling pathway, promoting cell proliferation and survival.
   - **TERT (telomerase reverse transcriptase)**: Promoter mutations upregulate telomerase activity, leading to immortalization of cancer cells.
   - **AXIN1**: Mutations in this negative regulator of Wnt signaling enhance β-catenin activity.
   - **ARID1A/ARID2**: Loss-of-
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 11: `ind_dc_c36faf6ef60d`
**Q**: What genes and pathways are associated with liver cancer? What are the key mechanisms?

### System A (GDgpt)
```
** Liver cancer is mechanistically linked to several oncogenes and tumor suppressors, including **KRAS**, **HRAS**, **PIK3CA**, **TP53**, **PSMA4**, **EGFR**, **FGF4**, and **RAC1**, which are ASSOCIATED_WITH liver cancer per the knowledge graph. **KRAS** and **HRAS** activate oncogenic pathways such as **RAS/MAPK** and **PI3K/AKT**, promoting uncontrolled cell growth and survival [LLM-inferred]. **PIK3CA** enhances tumor proliferation via the **PI3K/AKT** pathway [LLM-inferred]. **TP53**, a tumor suppressor, is INVOLVED_IN apoptosis regulation through pathways like **Activation of NOXA and PUMA**. **EGFR** signaling supports tumor growth and survival, while **RAC1** mediates cytoskeletal reorganization, facilitating cancer cell invasion and metastasis. Pathways ASSOCIATED_WITH liver cance
```

### System B (GPT-4o)
```
Liver cancer, primarily hepatocellular carcinoma (HCC), is associated with several key genes and pathways that regulate cell proliferation, survival, and genomic stability. Below are the major genes, pathways, and mechanisms involved:

### Key Genes:
1. **TP53**: Frequently mutated in HCC, leading to loss of tumor suppressor function and genomic instability.
2. **CTNNB1 (β-catenin)**: Activating mutations in CTNNB1 drive aberrant Wnt/β-catenin signaling, promoting proliferation.
3. **TERT (Telomerase Reverse Transcriptase)**: Promoter mutations increase telomerase activity, contributing to cellular immortality.
4. **AXIN1**: Inactivating mutations impair Wnt/β-catenin pathway regulation.
5. **ARID1A/ARID2**: Epigenetic regulators involved in chromatin remodeling, often mutated, leading to 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 12: `ind_dc_dbb1afa7f685`
**Q**: What genes and pathways are associated with lung cancer? What are the key mechanisms?

### System A (GDgpt)
```
Lung cancer pathogenesis is driven by several key mechanisms, as supported by the knowledge graph. The RAS/RAF/MAP kinase cascade pathway is activated through genes such as KRAS, HRAS, and NRAS, which are ASSOCIATED_WITH lung cancer and INTERACT_WITH this pathway, driving cell growth and survival. Dysregulation of the PI3K/AKT signaling pathway, involving PIK3CA, AKT1, and KIT, which are INTERACTS_WITH this pathway, promotes cell proliferation and resistance to apoptosis. Inflammatory pathways, including the Interleukin-4 and Interleukin-13 signaling pathway (involving NOS2, ALOX5, and VEGFA) and the Neutrophil degranulation pathway (involving ALOX5, TTR, and SERPINA1), contribute to tumor microenvironment remodeling. The tumor suppressor TP53, which is ASSOCIATED_WITH lung cancer, plays a
```

### System B (GPT-4o)
```
Lung cancer is associated with various genetic alterations and pathways that drive tumorigenesis, cell survival, and metastasis. Here is a concise summary of key genes, pathways, and mechanisms:

### Key Genes:
1. **Oncogenes:**
   - **EGFR**: Mutations (e.g., exon 19 deletions, exon 21 L858R) lead to constitutive activation of the EGFR signaling pathway.
   - **KRAS**: Mutations (e.g., G12C, G12D) are common in lung adenocarcinomas and activate downstream signaling pathways.
   - **ALK**: Rearrangements (e.g., EML4-ALK fusions) result in constitutive kinase activity.
   - **ROS1**: Fusions (e.g., CD74-ROS1) activate oncogenic signaling.
   - **MET**: Amplifications or exon 14 skipping mutations enhance MET signaling.
   - **BRAF**: V600E mutations lead to constitutive activation of the MA
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 13: `ind_dc_d130a7eb1f15`
**Q**: What genes and pathways are associated with adenocarcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
Adenocarcinoma of the liver and intrahepatic biliary tract is driven by mutations in oncogenes such as **KRAS**, **HRAS**, **PIK3CA**, and **EGFR**, which are ASSOCIATED_WITH this cancer subtype per the knowledge graph, and by the loss of tumor suppressor **TP53**, which is also ASSOCIATED_WITH the disease. These genetic alterations dysregulate canonical pathways, including **RAS/MAPK** and **PI3K/AKT/mTOR**, which are INVOLVED_IN tumorigenesis and uncontrolled cell proliferation. Additionally, cytoskeletal remodeling, facilitated by **RAC1** through its involvement in the **RHO GTPases Activate Formins** pathway, contributes to metastasis. Chromosomal instability mechanisms, such as the **Resolution of Sister Chromatid Cohesion** and **Separation of Sister Chromatids** pathways, which inv
```

### System B (GPT-4o)
```
Adenocarcinoma of the liver and intrahepatic biliary tract (encompassing hepatocellular carcinoma [HCC] and intrahepatic cholangiocarcinoma [iCCA]) involves several genes and pathways that drive tumorigenesis. Below is a concise overview:

### 1. **Hepatocellular Carcinoma (HCC)**
   - **Key Genes**:
     - **TP53**: Frequently mutated, leading to loss of tumor suppressor function.
     - **CTNNB1 (β-catenin)**: Mutations drive Wnt/β-catenin pathway activation.
     - **TERT**: Promoter mutations result in telomerase activation and genomic stability.
     - **AXIN1**: Mutations impair Wnt pathway regulation.
     - **ARID1A/ARID2**: Chromatin remodeling gene mutations contribute to epigenetic dysregulation.
   
   - **Key Pathways**:
     - **Wnt/β-catenin pathway**: Aberrant activation pr
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 14: `ind_dc_8df2021cf75b`
**Q**: What genes and pathways are associated with undifferentiated carcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
Undifferentiated carcinoma of the liver and intrahepatic biliary tract is strongly ASSOCIATED_WITH oncogenes such as **KRAS**, **HRAS**, and **PIK3CA**, as well as the tumor suppressor gene **TP53**, according to the knowledge graph. Mechanistically, **KRAS** and **HRAS** are INVOLVED_IN the activation of the RAS/RAF/MEK/ERK signaling pathway, which PROMOTES cell proliferation and survival (KG: KRAS/HRAS–interacts with–Activated NTRK2/3 signals through RAS). **PIK3CA** is ASSOCIATED_WITH the PI3K/AKT/mTOR pathway, which ENHANCES cellular growth and survival (KG: PIK3CA–associated with–Disease). **TP53**, a critical tumor suppressor, is frequently mutated in this carcinoma type, and its loss of function is ASSOCIATED_WITH genomic instability and resistance to apoptosis (KG: TP53–associated 
```

### System B (GPT-4o)
```
Undifferentiated carcinoma of the liver and intrahepatic biliary tract is rare, and its molecular underpinnings are not fully characterized. However, based on available data, key genes and pathways potentially associated with this tumor type include:

### Associated Genes:
1. **TP53**: Frequently mutated in poorly differentiated or aggressive liver and biliary tract cancers, leading to impaired DNA damage response and cell cycle regulation.
2. **KRAS**: Activating mutations in KRAS are common in intrahepatic cholangiocarcinoma, driving growth and proliferation through MAPK/ERK signaling.
3. **IDH1/IDH2**: Mutations in these genes are seen in cholangiocarcinoma, resulting in abnormal 2-hydroxyglutarate production and epigenetic dysregulation.
4. **FGFR2**: Fusions in FGFR2 are specifically 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 15: `ind_dc_f30ad13c7079`
**Q**: What genes and pathways are associated with squamous cell carcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
Squamous cell carcinoma of the liver and intrahepatic biliary tract is ASSOCIATED_WITH genetic alterations in oncogenes such as **KRAS**, **HRAS**, **PIK3CA**, **EGFR**, **FGF4**, and **RAC1**, as well as the tumor suppressor **TP53**, per the knowledge graph. These mutations are INVOLVED_IN the dysregulation of key signaling pathways, including **RAS signaling** (e.g., "Activated NTRK2 signals through RAS"), **PI3K/AKT** (involving PIK3CA downstream of EGFR), **chromatid cohesion and separation** (e.g., "Resolution of Sister Chromatid Cohesion" and "Separation of Sister Chromatids" involving TP53), and **cytoskeletal remodeling** (e.g., "RHO GTPases Activate Formins" involving RAC1). These pathways drive hallmark cancer behaviors such as uncontrolled proliferation, genomic instability, an
```

### System B (GPT-4o)
```
Squamous cell carcinoma (SCC) of the liver and intrahepatic biliary tract is an extremely rare malignancy, and its molecular mechanisms are not well characterized. However, based on existing knowledge from biliary tract cancers and SCCs in other sites, several genes and pathways may be implicated:

### Key Genes and Pathways:
1. **TP53**: Mutations in TP53 are frequently observed in biliary tract cancers and SCCs, leading to loss of cell cycle regulation and genomic instability.

2. **KRAS**: Mutations in KRAS are common in biliary tract cancers and may play a role in SCC transformation by activating the MAPK/ERK signaling pathway.

3. **PIK3CA/AKT/mTOR Pathway**: Dysregulation of this pathway, through PIK3CA mutations or PTEN loss, is implicated in various SCCs and biliary tract malignanc
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |
